Literature DB >> 15984335

Application of DIVA vaccines and their companion diagnostic tests to foreign animal disease eradication.

John Pasick1.   

Abstract

The risk of foreign animal disease introduction continues to exist despite Canada's strict regulations concerning the importation of animals and animal products. Given the rapidity with which these diseases can spread, especially in areas with dense livestock populations, eradication efforts which rely solely on quarantine and stamping-out measures can present a formidable undertaking. This, combined with growing economic and ethical considerations, has led to renewed interest in the use of vaccination as a tool in controlling foreign animal disease outbreaks. Vaccination has effects at the individual and population levels. Efficacious vaccines reduce or prevent clinical signs without necessarily preventing virus replication. They may also increase the dose of virus needed to establish an infection and/or reduce the level and duration of virus shedding following infection. Vaccine effectiveness within a population is a function of its ability to reduce virus transmission. Transmission is best described by the reproductive ratio, R, which is defined as the average number of new infections caused by one infectious individual. By helping to reduce the R-value below 1, vaccination can be an effective adjunct in abbreviating an outbreak. Nevertheless, vaccination can also complicate serological surveillance activities that follow eradication, if the antibody response induced by vaccination is indistinguishable from that which follows infection. This disadvantage can be overcome by the use of DIVA vaccines and their companion diagnostic tests. The term DIVA (differentiating infected from vaccinated individuals) was coined in 1999 by J. T. van Oirschot of the Central Veterinary Institute, in The Netherlands. It is now generally used as an acronym for 'differentiating infected from vaccinated animals'. The term was originally applied to the use of marker vaccines, which are based on deletion mutants of wild-type microbes, in conjunction with a differentiating diagnostic test. The DIVA strategy has been extended to include subunit and killed whole-virus vaccines. This system makes possible the mass vaccination of a susceptible animal population without compromising the serological identification of convalescent individuals. The DIVA approach has been applied successfully to pseudorabies and avian influenza eradication, and has been proposed for use in foot-and-mouth disease and classical swine fever eradication campaigns. This paper will survey current vaccine technology, the host immune response, and companion diagnostic tests that are available for pseudorabies, foot-and-mouth disease, classical swine fever and avian influenza.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15984335     DOI: 10.1079/ahr200479

Source DB:  PubMed          Journal:  Anim Health Res Rev        ISSN: 1466-2523            Impact factor:   2.615


  15 in total

1.  Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine.

Authors:  Jürgen A Richt; Porntippa Lekcharoensuk; Kelly M Lager; Amy L Vincent; Christina M Loiacono; Bruce H Janke; Wai-Hong Wu; Kyoung-Jin Yoon; Richard J Webby; Alicia Solórzano; Adolfo García-Sastre
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide.

Authors:  Carolina Cubillos; Beatriz G de la Torre; Annamaria Jakab; Giorgia Clementi; Eva Borrás; Juan Bárcena; David Andreu; Francisco Sobrino; Esther Blanco
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

3.  Inclusion of a specific T cell epitope increases the protection conferred against foot-and-mouth disease virus in pigs by a linear peptide containing an immunodominant B cell site.

Authors:  Carolina Cubillos; Beatriz G de la Torre; Juan Bárcena; David Andreu; Francisco Sobrino; Esther Blanco
Journal:  Virol J       Date:  2012-03-14       Impact factor: 4.099

4.  Recombinant M2e protein-based ELISA: a novel and inexpensive approach for differentiating avian influenza infected chickens from vaccinated ones.

Authors:  Farhid Hemmatzadeh; Sumarningsih Sumarningsih; Simson Tarigan; Risa Indriani; N L P Indi Dharmayanti; Esmaeil Ebrahimie; Jagoda Igniatovic
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

5.  Future vaccines for a globalized world.

Authors:  Lorne A Babiuk; Volker Gerdts
Journal:  Emerg Microbes Infect       Date:  2012-07       Impact factor: 7.163

6.  Immunization with a Borrelia burgdorferi BB0172-derived peptide protects mice against lyme disease.

Authors:  Christina M Small; Dharani K Ajithdoss; Aline Rodrigues Hoffmann; Waithaka Mwangi; Maria D Esteve-Gassent
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

7.  A proteomic approach to the development of DIVA ELISA distinguishing pigs infected with Salmonella Typhimurium and pigs vaccinated with a Salmonella Typhimurium-based inactivated vaccine.

Authors:  Jan Gebauer; Hana Kudlackova; Marcel Kosina; Kamil Kovarcik; Radek Tesarik; Alena Osvaldova; Martin Faldyna; Jan Matiasovic
Journal:  BMC Vet Res       Date:  2016-11-11       Impact factor: 2.741

8.  Immunity of foot-and-mouth disease serotype Asia 1 by sublingual vaccination.

Authors:  Hao-tai Chen; Yong-sheng Liu
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  Pseudorabies virus variant in Bartha-K61-vaccinated pigs, China, 2012.

Authors:  Tong-Qing An; Jin-Mei Peng; Zhi-Jun Tian; Hong-Yuan Zhao; Na Li; Yi-Min Liu; Jia-Zeng Chen; Chao-Liang Leng; Yan Sun; Dan Chang; Guang-Zhi Tong
Journal:  Emerg Infect Dis       Date:  2013-11       Impact factor: 6.883

Review 10.  Review: Capripoxvirus Diseases: Current Status and Opportunities for Control.

Authors:  E S M Tuppurainen; E H Venter; J L Shisler; G Gari; G A Mekonnen; N Juleff; N A Lyons; K De Clercq; C Upton; T R Bowden; S Babiuk; L A Babiuk
Journal:  Transbound Emerg Dis       Date:  2015-11-13       Impact factor: 5.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.